• Home
  • Outline
  • Members
  • Report
  • Contact

Report

Publications

  1. Miyamoto, N.: Utilization of iPSC technologies for drug-induced risk and drug efficacy evaluation during drug development. Curr. Pharm. Biotechnol. 21 (9): 750 – 751 (2020).
  2. Inoue, T., Iwazaki, N., Araki, T., and Hitotsumachi, H.: Human-induced pluripotent stem cell-derived hepatocytes and their culturing methods to maintain liver functions for pharmacokinetics and safety evaluation of pharmaceuticals. 21 (9): 773 – 779 (2020).
  3. Shirakawa, T., and Suzuki, I.: Approach to neurotoxicity using human iPSC neurons: Consortium for Safety Assessment using Human iPS Cells. Curr. Pharm. Biotechnol. 21 (9): 780 – 786 (2020).
  4. Matsui, T., Miyamoto, N., Saito, F., and Shinozawa, T.: Molecular profiling of human induced pluripotent stem cell-derived cells and their application for drug safety Study. Curr. Pharm. Biotechnol. 21 (9): 807 – 828 (2020).
  5. Takasuna, K., Kazusa, K., and Hayakawa, T.: Comprehensive cardiac safety assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi). Curr. Pharm. Biotechnol. 21 (9): 829 – 841 (2020).
  6. Yamazaki D., Kitaguchi T., Ishimura M., Taniguchi T., Yamanishi A., Saji D., Takahashi E., Oguchi M., Moriyama Y., Maeda S., Miyamoto K., Morimura K., Ohnaka H., Tashibu H., Sekino Y., Miyamoto N., Kanda Y.: Usefulness of human induced stem cell-derived cardiomyocytes for proarrhythmia risk prediction using 2-dimensional categorization system. J. Pharmacol Sci., 136: 249-256 (2018)
  7. Yumiko Nozaki: Development of new evaluation method to predict drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes. Thesis, Graduate School of Pharmaceutical Sciences, Osaka University, (2017)
  8. Takashi Kitaguchi: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia-effects. Thesis, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, (2017)
  9. Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Tanaka K, Takahashi E, Miyamoto K, Morimura A, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Shinozawa T, Saito F, Kunimatsu T.: CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul. Toxicol. Pharmacol., 88: 238-251 (2017) .
  10. Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N: CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods, 85: 73-81 (2017).
  11. Takasuna K, Asakura K, Araki S, Ando H, Kazusa K, Kitaguchi T, Kunimatsu T, Suzuki S, Miyamoto N: Complehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi Heart initiative. J. Pharmacol. Toxicoll Methods, 83: 42-54 (2017).
  12. Miyamoto N: Application of human iPS cell-derived cells for drug-induced risk assessment. Experimental Medicine, 34: 557-563 (2016).
  13. Araki T, Iwazaki N, Ishiguro N, Sakamoto A, Nagata K, Ohbuchi M, Moriguchi H, Motoi M, Shinkyo R, Homma T, Sakamoto S, Iwase Y, Ise R, Nakanishi Y, Uto M, Inoue T: Requirements for human iPS cell-derived hepatocytes as an alternative to primary human hepatocytes for assessing absorption, distribution, metabolism, excretion and toxicity of pharmaceuticals. Fundamental Toxicol. Sci., 3: 89-99 (2016).
  14. Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T: CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol., 77: 75-86 (2016).
  15. Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Morita M, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Tanaka K, Washio I, Miyamoto N, CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia –Effects of 7 reference compounds at 10 facilities–. J. Pharmacol. Toxicoll Methods, 78: 93-102 (2016).
  16. Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Nagasawa C, Kitamura T, Osada T, Honda Y, Kasai C, Ando H, Kanda Y, Sekino Y, Sawada K: Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J. Pharmacol. Toxicoll Methods, 75: 17-26 (2015).
  • Japan iPS Cardiac Safety Assessment (JiCSA)
  • Introduction of UK Scotland life science
Page Top